| 1 |
Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010;6:494-9.
DOI
|
| 2 |
Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost 2009;101:271-8.
|
| 3 |
de Córdoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151: 1-13.
|
| 4 |
Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204:1249-56.
DOI
ScienceOn
|
| 5 |
Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012 Aug;82:465-73.
|
| 6 |
Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012;7:748-56.
DOI
|
| 7 |
Servais A, Fremeaux-Bacchi V, Lequintrec M, Solomon R, Blouin J, Knebelmann B, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9.
|
| 8 |
Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-64.
DOI
ScienceOn
|
| 9 |
Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009;75:952-60.
DOI
ScienceOn
|
| 10 |
Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011;6:1009-17.
DOI
ScienceOn
|
| 11 |
Sethi S, Fervenza FC. Membranoproliferative glomerulone-phritis-a new look at an old entity. N Engl J Med 2012;366: 1119-31.
DOI
ScienceOn
|
| 12 |
Sethi S, Nester CM, Smith RJ. Membranoproliferative glome- rulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012;81:434-41.
DOI
ScienceOn
|
| 13 |
Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005;16:1392-403.
DOI
ScienceOn
|
| 14 |
Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012;82:465-73.
DOI
ScienceOn
|
webmaster
